EIP Pharma is a brand that specializes in treating neurodegenerative diseases such as Alzheimer’s, Dementia with Lewy Bodies, and Huntington’s disease. With a focus on intervening early in the disease process, EIP Pharma aims to reverse the synaptic dysfunction responsible for disease symptoms and progression. Their approach is backed by extensive scientific literature and promising preclinical and clinical results.

One of their key developments is Neflamapimod, an oral, selective small molecule inhibitor of the protein kinase p38 alpha. Research has shown that p38 alpha plays a crucial role in synaptic dysfunction, making it a target for intervention. Preclinical data and recent phase 2 clinical studies in dementia with Lewy bodies and Alzheimer’s disease suggest that Neflamapimod can reverse the synaptic dysfunction in the early stages of various neurological disorders.

EIP Pharma's dedication to treating neurodegenerative diseases offers hope to millions of individuals worldwide who suffer from memory loss, impaired cognitive function, and other debilitating symptoms. Contact EIP Pharma to learn more about their innovative treatments and the potential for a better future